










**Supplemental Figure.** Correlation between pre-existing antibody concentrations and reported COVID-19-related symptoms in symptomatic (n=64) and asymptomatic (n=4) health care workers with a PCR-confirmed SARS-CoV-2 infection. Significant p-values (<0.05) are indicated above the graph (one-way ANOVA using log<sub>2</sub>-transformed antibody concentrations). Horizontal lines show the geometric mean concentrations and 95% confidence intervals. \* p<0.05.

**Difficulty breathing****Fever****Fatigue/ness****Loss of taste/smell****Cough****Nausea/vomiting****Diarrhea****Loss of appetite****Muscle/body aches**

○ No symptoms      ● Other symptoms  
 ● Symptom highlighted in the graph

**Supplemental Table 1.** Participant characteristics.

	Total (N=2043)	Seropositive (N=55)	Seronegative (N=1988)	P-value
Age (in years), median (IQR)	36 (30-46)*	34 (29-44)	36 (30-46)*	0.293
Sex, n (%)				0.719
Male	502 (24.6)	17 (30.9)	485 (24.4)	
Female	1536 (75.2)	38 (69.1)	1498 (75.4)	
Other	2 (0.1)	0	2 (0.1)	
Unknown	3 (0.1)	0	3 (0.2)	
Race, n (%)				0.291
Asian	172 (8.4)	2 (3.6)	170 (8.6)	
Black	117 (5.7)	5 (9.1)	112 (5.6)	
White	1694 (82.9)	45 (81.8)	1649 (82.9)	
Other/multiracial	33 (1.6)	1 (1.8)	32 (1.6)	
Unknown	27 (1.3)	2 (3.6)	25 (1.3)	
Ethnicity, n (%)				0.293
Hispanic	71 (3.5)	4 (7.3)	67 (3.4)	
Non-Hispanic	1971 (96.5)	51 (92.7)	1920 (96.6)	
Unknown	1 (<0.1)	0	1 (0.1)	

\* Age was not reported for 1 participant.

**Supplemental Table 2.** Characteristics of 64 participants who had no detectable S-RBD antibodies during the spring and summer of 2020 and reported via the online survey that they had a symptomatic lab-confirmed SARS-CoV-2 infection after the last blood draw.

	<b>Total (N=64)</b>
<b>Symptoms, n (%)</b>	
Cough	42 (65.6)
Fever or chills	42 (65.6)
Nausea/vomiting	13 (20.3)
Diarrhea	20 (31.3)
Unusual fatigue	51 (79.7)
Loss of taste or smell	47 (73.4)
Difficulty breathing	17 (26.6)
Loss of appetite	34 (53.1)
Muscle/body aches	45 (70.3)
Other	23 (35.9)
<b>Estimated date of SARS-CoV-2 infection, n (%)</b>	
July 2020	6 (9.4)
August 2020	1 (1.6)
September 2020	0
October 2020	9 (14.1)
November 2020	14 (21.9)
December 2020	30 (46.9)
January 2021	4 (6.3)
<b>Resolution of symptoms, n (%)</b>	
Within 7 days	13 (20.3)
Within 1 month	32 (50.0)
More than 1 month	13 (20.3)
Unknown	6 (9.4)
<b>Hospitalization because of COVID-19, n (%)</b>	<b>2 (3.1)</b>

**Supplemental Table 3.** Effects of log<sub>2</sub> pre-existing antibody titers, age and sex on symptom duration (days) via multivariate regression.

	<b>Estimate</b>	<b>SE</b>	<b>P-value</b>
S-FL	-2.731	2.685	0.313
Age	3.204	2.697	0.240
Sex (male)	5.675	7.964	0.479
N	1.895	2.698	0.485
Age	3.606	2.712	0.189
Sex (male)	6.299	7.997	0.434
OC43	-8.166	2.739	0.004
Age	0.170	2.752	0.951
Sex (male)	4.226	7.498	0.575
HKU1	-5.867	2.630	0.030
Age	2.392	2.644	0.369
Sex (male)	5.559	7.704	0.474
NL63	-2.354	2.683	0.384
Age	3.548	2.697	0.194
Sex (male)	6.218	7.973	0.439
229E	-3.054	2.846	0.288
Age	2.840	2.742	0.305
Sex (male)	8.483	8.255	0.308